Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Transfusion01:15

Blood Transfusion

Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alpha-gal Immunoglobulin E Seroprevalence Among Blood Donors - 10 States, 2024-2025.

MMWR. Morbidity and mortality weekly report·2026
Same author

Red Blood Cell Transfusion Characteristics and Morbidity or Mortality in Very-Low-Birth-Weight Infants.

JAMA network open·2026
Same author

An international study on emerging arboviral infections and blood safety.

Transfusion·2026
Same author

Entropy-Driven Ligand Exchange in a Rotationally Flexible Dinuclear Fe(II)-Fe(II) Complex.

Inorganic chemistry·2026
Same author

First-time blood donor demographics and characteristics during the individual donor assessment versus 3-month deferral policies for high-risk behaviors.

Transfusion·2026
Same author

Integrated analysis of blood donor metabolic phenotypes and genetic traits on red blood cell transfusion effectiveness.

Blood. Red cells & iron·2026
Same journal

Investigation of the preanalytical stability of blood donor samples.

Transfusion·2026
Same journal

The need for dried plasma-Still a national issue: Where are we and recommendations.

Transfusion·2026
Same journal

Spray dried plasma manufactured from apheresis and whole blood derived plasma.

Transfusion·2026
Same journal

Identification of a novel ABO*A1.01 allele with c.562C>T (p.Arg188Cys) mutation associated with A<sub>el</sub> phenotype in a Chinese individual.

Transfusion·2026
Same journal

AABB survey on directed blood donation practices.

Transfusion·2026
Same journal

Cost analysis considerations for red blood cell matching to mitigate alloimmunization in patients with sickle cell disease.

Transfusion·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Defining "adequate" pathogen reduction performance for transfused blood components.

Raymond P Goodrich1, Brian Custer, Shawn Keil

  • 1CaridianBCT Biotechnologies, LLC, Lakewood, Colorado 80215, USA. ray.goodrich@caridianbct.com

Transfusion
|April 9, 2010
PubMed
Summary
This summary is machine-generated.

Pathogen reduction technologies for labile blood products are crucial for transfusion safety. This study evaluates if current plasma product standards apply to labile components, proposing alternative performance criteria.

More Related Videos

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

Related Experiment Videos

Last Updated: Jun 14, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

Area of Science:

  • Blood banking and transfusion medicine.
  • Microbiology and infectious diseases.
  • Biotechnology and medical device development.

Background:

  • Pathogen reduction technologies (PRT) protect against transfusion-transmitted infections.
  • Current PRT methods for plasma products are not directly transferable to labile blood components.
  • Advancements in pathogen detection and PRT necessitate re-evaluation of safety standards.

Purpose of the Study:

  • To assess the applicability of existing pathogen reduction criteria (6 log10 reduction) for plasma derivatives to labile blood products.
  • To propose suitable performance criteria for PRT of labile blood components.
  • To inform the blood banking community on optimizing transfusion safety through PRT.

Main Methods:

  • Review of pathogen dynamics, infectivity, and transmission by blood products.
  • Analysis of historical and current pathogen testing methodologies (serology, nucleic acid testing).
  • Evaluation of the performance characteristics of available pathogen reduction technologies.

Main Results:

  • Existing PRT methods for plasma are not directly suitable for labile blood products due to differing mechanisms of action.
  • A critical review of pathogen reduction efficacy and safety is needed for labile components.
  • Current PRT technologies offer varying levels of pathogen inactivation.

Conclusions:

  • The stringent 6 log10 reduction standard for plasma derivatives may not be directly applicable or sufficient for labile blood products.
  • Developing specific performance criteria for labile blood component PRT is essential.
  • Further research is needed to establish optimal PRT strategies for enhancing transfusion safety.